» Articles » PMID: 24160821

Yttrium-90 Radioembolization As a Bridge to Liver Transplantation: a Single-institution Experience

Overview
Date 2013 Oct 29
PMID 24160821
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate our experience with the use of yttrium-90 ((90)Y) radioembolization in maintaining potential candidacy and, in some instances, downstaging hepatocellular carcinoma (HCC) that does not meet Milan criteria for liver transplantation.

Materials And Methods: A retrospective review of 20 consecutive patients with HCC who were listed to receive a liver transplant and were treated with (90)Y radioembolization as a sole modality for locoregional "bridge" therapy was performed. Demographics, radiographic and pathologic response, survival, and recurrences were examined.

Results: Twenty-two (90)Y treatments were performed in 20 patients before transplantation. Median time from first treatment to transplantation was 3.5 months. HCC in 14 patients met the Milan criteria at the time of the first (90)Y treatment, and HCC in six did not. All cases that originally met the Milan criteria remained within the criteria before transplantation, and two of six patients whose disease did not meet the criteria (33%) had their disease successfully downstaged to meet the criteria. Overall, nine patients (45%) had complete or partial radiologic response to (90)Y radioembolization according to modified Response Evaluation Criteria In Solid Tumors. Complete necrosis of tumor with no evidence of viable tumor on pathologic examination was observed in five patients (36%) whose disease met the Milan criteria.

Conclusions: Particularly in regions with long wait list times, (90)Y treatment is effective in maintaining tumor size in potential liver transplantation candidates with HCC. In addition, it can also be considered as a downstaging therapy in select patients before transplantation.

Citing Articles

Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging.

Zeimpekis K, Sari H, Gozlugol N, Achangwa N, Shi K, Schindewolf M Eur J Nucl Med Mol Imaging. 2024; 52(4):1460-1471.

PMID: 39730786 PMC: 11839895. DOI: 10.1007/s00259-024-07034-9.


Selective internal radiation therapy for unresectable HCC: The SIRT downstaging study.

Regnault H, Chalaye J, Galetto-Pregliasco A, Perrin C, Derbel H, Amaddeo G Hepatol Commun. 2024; 8(7).

PMID: 38934702 PMC: 11213600. DOI: 10.1097/HC9.0000000000000475.


Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin-bilirubin score's prediction factor for survival?.

Evirgen S, Cavus B, Gokturk S, Iliaz R, Ozkan Z, Baran B Hepatol Forum. 2023; 4(3):103-107.

PMID: 37822305 PMC: 10564249. DOI: 10.14744/hf.2022.2022.0036.


Antitumor Activity of Metformin Combined with Locoregional Therapy for Liver Cancer: Evidence and Future Directions.

Choksi E, Elsayed M, Kokabi N Cancers (Basel). 2023; 15(18).

PMID: 37760509 PMC: 10526211. DOI: 10.3390/cancers15184538.


Selecting the Appropriate Downstaging and Bridging Therapies for Hepatocellular Carcinoma: What Is the Role of Transarterial Radioembolization? A Pooled Analysis.

Lopez-Lopez V, Miura K, Kuemmerli C, Capel A, Eshmuminov D, Ferreras D Cancers (Basel). 2023; 15(7).

PMID: 37046783 PMC: 10093460. DOI: 10.3390/cancers15072122.